Masking CD3 before getting exposed in the TME, enables manageble peripheral T cell activation while maximizing intratumoral T cell infiltration, activation, persistence and tumor killing. 

Incoporating CD2 adhesion and costim into TCE design enables optimal T cell activation and persistence, thus more robust tumor-killing while achiving manageble CRS risk.